Engineering NIR Probes to Enhance Affinity and Clinical Workflow Compatibility for Prostate Cancer Imaging

G Gauri S. Malankar (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) D Dani A. Szafran (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) G Gourav Kumar (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) J Joshua Pace (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) M Mackenzie Devereux (Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland Oregon 97201 USA) K Kai Tao M Michelle Gomes (Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland Oregon 97201 USA) W William S. Greer (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) C Cody C. Rounds (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) A Anas M. Masillati (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) S Seseel Gergis (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) H Hayden Ledvina (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) K Kyle J. Milnes (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) M Melissa H. Wong M Mark J. Niedre (Department of Bioengineering Northeastern University Boston Massachusetts 02115 USA) S Summer L. Gibbs (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA) L Lei G. Wang (Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA)

Abstract

Abstract Positive surgical margins following radical prostatectomy increase the risk of biochemical recurrence and subsequent disease progression. Fluorescence‐guided surgery (FGS) using targeted contrast agents has shown clinical benefits for several cancer types. However, current prostate cancer targeted imaging probes exhibit long pharmacokinetic (PK) profiles, necessitating extended waiting periods or repeated hospital visits, limiting their integration into standard clinical workflow. To overcome this critical clinical compatibility challenge, we developed an innovative tri‐compartment, chemistry‐driven probe design strategy. Specifically, we developed a congeneric library of near infrared (NIR) water soluble fluorescent probes incorporating: 1) a glutamic acid‐urea‐lysine (EuK) ligand targeting prostate specific membrane antigen (PSMA); 2) a NIR heptamethine cyanine fluorophore optimized for enhanced PSMA binding via secondary binding site interactions; and 3) distinct PK modulators residing outside the PSMA binding pocket to promote rapid off‐target tissue clearance. While molecular docking scores, photophysical properties and live‐cell staining results showed similar overall performance, probes bearing PK modulators produced stronger tumor‐specific fluorescence and accumulation in vivo than the control probe lacking a PK modulator. This effort enabled identification of a lead probe with robust tumor targeting and accelerated off‐target clearance, providing optimal tumor‐specific signal and contrast in a timeframe, fully compatible with robotic‐assisted radical prostatectomy (RARP) timelines.

Article Details

Volume / Issue Vol. 65, Issue 31
Published July 27, 2026
ISSN 1433-7851
Publisher Wiley

Journal Info

Angewandte Chemie International Edition

Wiley

ISSN: 1433-7851 Physical Sciences

Authors (17)

G

Gauri S. Malankar

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

D

Dani A. Szafran

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

G

Gourav Kumar

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

J

Joshua Pace

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

M

Mackenzie Devereux

Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland Oregon 97201 USA

K

Kai Tao

M

Michelle Gomes

Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland Oregon 97201 USA

W

William S. Greer

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

C

Cody C. Rounds

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

A

Anas M. Masillati

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

S

Seseel Gergis

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

H

Hayden Ledvina

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

K

Kyle J. Milnes

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

M

Melissa H. Wong

M

Mark J. Niedre

Department of Bioengineering Northeastern University Boston Massachusetts 02115 USA

S

Summer L. Gibbs

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA

L

Lei G. Wang

Department Biomedical Engineering Oregon Health & Science University Portland Oregon 97201 USA